Study defines follow-up standards for early-stage lung cancer

Share this content:
Long-term follow-up strategies can be defined for patients with early-stage lung cancer, according to a study published in the Journal of Thoracic Oncology (2010 Aug;5(8):1246-50).

For the study, led by Ryo Maeda, MD, researchers identified 519 patients with stage IA non-small cell lung cancer (NSCLC) who underwent complete resection and quantified the risk of late recurrence for those who remained recurrence-free for more than 5 years after complete tumor resection.

The results of the study revealed that in patients with stage IA NSCLC without vascular invasion, 5 years may be sufficient to declare that the patients are cured. However, researchers determined that patients with stage IA NSCLC with vascular invasion need follow-up until at least 9 years after resection.

The research team identified the presence of vascular invasion as one independent significant predictor of late recurrence in stage IA 5-year recurrence-free survivors. Specifically, the 5-year recurrence-free probability from the benchmark was 84% for patients with vascular invasion and 95% for patients without vascular invasion.

“If they are recurrence-free, patients without vascular invasion may be declared cured at 5 years after resection,” noted Dr. Maeda. “On the other hand, patients with stage IA NSCLC with vascular invasion, 5 years without recurrence is not sufficient to conclude that NSCLC is cured.”
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs